Lexicon (NASDAQ: LXRX) SVP nets shares after RSU vesting on Feb 28

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS, INC. senior vice president of Discovery, Suma Gopinathan, reported multiple equity compensation transactions. On February 28, 2026, she acquired common stock through the exercise and conversion of restricted stock units in blocks of 14,000, 20,310 and 65,640 shares, each at a conversion price of $0.0000 per share. A separate transaction disposed of 24,338 shares of common stock at $1.4700 per share to cover tax withholding obligations, leaving her with 150,132 directly held common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gopinathan Suma

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Discovery

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/28/2026		M		14,000	A	(1)	88,520	D
Common Stock	02/28/2026		M		20,310	A	(1)	108,830	D
Common Stock	02/28/2026		M		65,640	A	(1)	174,470	D
Common Stock	02/28/2026		F(2)		24,338	D	$1.47	150,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/28/2026		M			14,000	(3)	(3)	Common Stock	14,000	(1)	0	D
Restricted Stock Units	(1)	02/28/2026		M			20,310	(3)	(3)	Common Stock	20,310	(1)	20,310	D
Restricted Stock Units	(1)	02/28/2026		M			65,640	(3)	(3)	Common Stock	65,640	(1)	131,280	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

3. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

	/s/ Suma Gopinathan, M.S, Ph.D.	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Lexicon Pharmaceuticals (LXRX) report for Suma Gopinathan?

Lexicon Pharmaceuticals reported that SVP, Discovery, Suma Gopinathan exercised and converted restricted stock units into common shares and had a portion of the resulting stock withheld to satisfy tax obligations, as disclosed in a Form 4 insider trading report.

How many Lexicon (LXRX) restricted stock units did Suma Gopinathan convert?

Suma Gopinathan converted restricted stock units into common stock in three blocks of 14,000, 20,310 and 65,640 units. Each restricted stock unit represents a contingent right to receive one share of Lexicon Pharmaceuticals common stock, according to the filing footnotes.

What was the purpose of the 24,338-share disposition in the Lexicon (LXRX) Form 4?

The 24,338-share disposition was for tax withholding. Lexicon withheld a portion of the shares issued upon restricted stock unit vesting to satisfy Gopinathan’s tax obligations, at a reported price of $1.4700 per share, rather than an open-market sale.

How many Lexicon Pharmaceuticals (LXRX) shares does Suma Gopinathan hold after these transactions?

After the reported restricted stock unit conversions and tax-withholding share disposition, Suma Gopinathan directly owns 150,132 shares of Lexicon Pharmaceuticals common stock, as stated in the Form 4’s post-transaction ownership figures.

How do Lexicon (LXRX) restricted stock units vest for Suma Gopinathan?

Restricted stock units for Suma Gopinathan vest in three equal installments. One-third of the shares underlying each award vest on February 28 of each of the three years following the year of grant, according to the footnotes in the Form 4 filing.

Does the Lexicon (LXRX) Form 4 show a market purchase or sale by Suma Gopinathan?

The Form 4 shows derivative exercises and a tax-withholding disposition, not an open-market trade. The transactions are coded as option-like conversions (code M) and a tax-related share withholding (code F) linked to restricted stock unit vesting.